

Larynx/Levisticum comp. PlantaVet

Authorised

- NERVUS LARYNGEUS RECURRENS BOVIS GL DIL. D5 (HAB, VS. 41A)
- NERVUS LARYNGEUS SUPERIOR BOVIS GL DIL. D5 (HAB, VS. 41A)
- LARYNX BOVIS GL DIL. D5 (HAB, VS. 41B)
- NERVUS VAGUS BOVIS GL DIL. D5 (HAB, VS. 41A)
- Levisticum officinale D5

Product identification

Medicine name:

Larynx/Levisticum comp. PlantaVet

Active substance:

NERVUS LARYNGEUS RECURRENS BOVIS GL DIL. D5 (HAB, VS. 41A)

NERVUS LARYNGEUS SUPERIOR BOVIS GL DIL. D5 (HAB, VS. 41A)

LARYNX BOVIS GL DIL. D5 (HAB, VS. 41B)

NERVUS VAGUS BOVIS GL DIL. D5 (HAB, VS. 41A)

Levisticum officinale D5

Target species:

Horse

Route of administration:

Intramuscular use

Subcutaneous use

Product details

Active substance and strength:

NERVUS LARYNGEUS RECURRENS BOVIS GL DIL. D5 (HAB, VS. 41A)

1.00 gram(s) / 10.00 millilitre(s)

NERVUS LARYNGEUS SUPERIOR BOVIS GL DIL. D5 (HAB, VS. 41A)

1.00 gram(s) / 10.00 millilitre(s)

LARYNX BOVIS GL DIL. D5 (HAB, VS. 41B)

1.00 gram(s) / 10.00 millilitre(s)

NERVUS VAGUS BOVIS GL DIL. D5 (HAB, VS. 41A)

1.00 gram(s) / 10.00 millilitre(s)

Levisticum officinale D5

1.00 gram(s) / 10.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Horse

- Meat and offal. 0 day

- Milk. 0 day

Subcutaneous use:

-

Horse

- Meat and offal. 0 day

- Milk. 0 day

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Available in:

Germany

Package description:

Available only in German

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Legal basis reviewed according to Acquis communautaire

Marketing authorisation holder:

SaluVet GmbH

Marketing authorisation date:

27/12/2005

Manufacturing sites for batch release:

Wala-Heilmittel GmbH

Responsible authority:

Federal Office Of Consumer Protection And Food Safety

Authorisation number:

6442763.00.00

Date of authorisation status change:

27/12/2005

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet